MR Fingerprinting for Diagnostic of Prostate Cancer

NCT05498623 | Completed

• 1 other identifier: 218665
• Study Type: observational
• Target: 203
• Locations: 1 country
• Sites: 1

Brief Summary

The diagnostic pathway for suspected prostate cancer relies greatly on radiological imaging. Establishment of magnetic resonance fingerprinting (MRF) has the potential to significantly improve patient experience and outcomes. MRF is a novel and innovative approach to a long-standing challenge of recording and reconstructing MR image The aim is to conduct a clinical pilot study in which patients will be scanned using the newly refined MRF sequence in addition to the conventional scanning protocols.

Conditions

Prostate Cancer; Magnetic Resonance Imaging

Keywords

MR Fingerprinting; Prostate Cancer

Outcome Measures

Primary Outcomes (1)

• MRF compared to T1, T2 and proton density generated to the PIRADS scoring

  MR Fingerprinting has proven to reduce scan time by acquiring property maps simultaneously. MRF uses pseudorandom, rapidly switching pulses to elicit a unique signal evolution - hence the term fingerprint. This "fingerprint" signal is matched to a predefined dictionary of all possible signal evolutions and so multiple measurements are acquired simultaneously. Since the values such as T1, T2 and proton density are matched and not interpolated, the method is far more quantitative than conventional MRI.

  an average of 30 minutes

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Healthy volunteers will be recruited among students and employees at NTNU/St. Olavs Hospital. The possibility to participate will be announced on internal WEB-pages and on bulletin boards at Øya Campus. Patients referred to mp-MRI due to suspicion of prostate cancer will receive information about the study and the informed consent form together with the letter they receive from Clinic of Radiology with their appointment for the MRI examination.

You may qualify if:

• \- Men referred to an MR examination for prostate cancer diagnostic

You may not qualify if:

• \- None

Sponsors & Collaborators

• Norwegian University of Science and Technology: lead
• St. Olavs Hospital: collaborator

Study Sites (1)

St Olavs Hospital

Trondheim, Norway

Location

Related Publications (2)

• Ma D, Gulani V, Seiberlich N, Liu K, Sunshine JL, Duerk JL, Griswold MA. Magnetic resonance fingerprinting. Nature. 2013 Mar 14;495(7440):187-92. doi: 10.1038/nature11971.

  PMID: 23486058 BACKGROUND

• Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, Margolis D, Schnall MD, Shtern F, Tempany CM, Thoeny HC, Verma S. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol. 2016 Jan;69(1):16-40. doi: 10.1016/j.eururo.2015.08.052. Epub 2015 Oct 1.

  PMID: 26427566 BACKGROUND

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 5, 2022
• First Posted: August 12, 2022
• Study Start: September 1, 2022
• Primary Completion: February 28, 2023
• Study Completion: March 15, 2023
• Last Updated: November 1, 2024

Record last verified: 2024-10

Locations

NO (1)